Changes in P2X4 receptor expression following AbobotulinumtoxinA treatment in patients with chronic migraine: A case series study.

Chronic migraine (CM) is a serious condition that affects many people. AbobotulinumtoxinA (ABO-BoNT-A) is a common treatment for CM. However, how it works at a molecular level isn’t fully understood. This research looked at changes in specific genes after ABO-BoNT-A treatment. The study focused on three genes: NTRK2, SRCIN1, and P2X4R. Researchers analyzed blood samples from eight patients with CM and medication overuse. They measured the levels of these genes before and after treatment using a technique called qRT-PCR. The results showed changes in gene expression that could help explain how ABO-BoNT-A works. Understanding these changes may lead to better treatment strategies for chronic migraine. This research highlights the importance of studying gene expression in patients receiving migraine treatments. Further investigation could help improve outcomes for individuals suffering from chronic migraine and related conditions. Clinical relevance: This study suggests that monitoring P2X4 receptor changes could improve chronic migraine treatment outcomes for patients receiving abobotulinumtoxinA therapy.